Precision Oncology: When Is a Cancer Mutation Truly Actionable?
Dr. Debyani Chakravarty on evidence standards, genomic uncertainty and the clinical limits of mutation–drug matching A mutation listed beside a therapy on a sequencing report may carry implications ranging from representing a regulatory-level biomarker to a preliminary biological hypothesis. An...